ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

4 links0 made here, not in the record10 judgments3 judges (the rules as one: Rule based)1 record change seen2 read an older version
Claude Opus 5.5Model not recordedRule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05353439Testing of Tazemetostat inCombination With Topotecanand Pembrolizumab inPatients With RecurrentSmall Cell Lung CancerNational Cancer Institute (NCIPhase 1 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 10 · ClinicalTrials.gov record · Version of 2026-11-10Nov 10 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSSmall Cell Lung CarcinomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSPembrolizumabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 16 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · TestedBackground · establishedTazemetostatEntry “Tazemetostat Hydrobromide”, re…›Nov 1 · A model not recorded · TestedNov 18 · Rule based · BackgroundBackgroundTopotecanEntry “Topotecan Hydrochloride”, read…›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pembrolizumab”the record gives no role
→judged=agrees→changed
How the 3 judgments split67%of judgments with a known value say Background · established
Background · 2
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1PembrolizumabA model not recordedBackgroundReplaced
Nov 1TazemetostatA model not recordedTestedRead an older version
Nov 1TopotecanA model not recordedBackgroundRead an older version
Nov 10The record itselfClinicalTrials.gov recordVersion of 2026-11-10Record change
Nov 10The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16PembrolizumabClaude Opus 5.5Background · establishedCurrent
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18TazemetostatRule based · role ruleBackgroundOverridden
Nov 18TopotecanRule based · role ruleTestedOverridden
As of nowSmall Cell Lung CarcinomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.